Who is suitable for a ChondroFiller injection in the thumb or hand

Could a ChondroFiller injection help with thumb or hand joint arthritis? For most patients asking that question, the answer depends less on X-ray grade or age than on what the imaging actually shows about the joint.

The clearest candidacy signal comes from Corain et al. (2023), a prospective study of 43 patients with trapeziometacarpal (thumb CMC) osteoarthritis. Patients ranged across the full Eaton-Littler spectrum — Stage I through Stage IV — and both the early and advanced groups achieved significant improvements in pain, function, and grip strength at six months. Staging does not gate access to this treatment.

A few practical markers help frame eligibility:

• Age — there is no upper age limit for ChondroFiller injection at London Cartilage Clinic.
• Defect size — there is no defect-size cutoff; larger or multi-compartment joints may require additional product, confirmed at consultation.
• 'Bone on bone' changes — advanced X-ray appearances do not automatically rule a patient out; individual imaging review determines suitability.
• Contraindications — active joint infection, active inflammatory arthritis (such as rheumatoid disease in a flare), and structural instability of the joint are generally incompatible with the procedure.

Beyond the thumb CMC, the injection is positioned for other small, highly constrained hand joints — including MCP and IP joints — where surgical alternatives are limited. Definitive suitability is established at the formal one-hour assessment, where prior imaging is reviewed and a written treatment plan is agreed.

Why the thumb CMC and small hand joints suit this treatment

The trapeziometacarpal joint — where the thumb's base meets the trapezium bone of the wrist — handles the pinch and grip forces involved in almost every daily task, from opening jars to holding a pen. When the cartilage lining that surface wears down, those forces transmit directly to bone, producing pain that is disproportionate to the joint's size.

Surgical reconstruction of the thumb CMC is genuinely difficult. The confined anatomy leaves little room for grafts or implants, and common procedures such as trapeziectomy involve removing bone and restructuring soft tissue under general anaesthetic, with weeks of immobilisation that follow. Smaller joints — the metacarpophalangeal and interphalangeal joints — present similar constraints. Operating on them carries meaningful risks of stiffness and functional loss, so non-operative options are frequently the preferred first line.

ChondroFiller Liquid works with this anatomy rather than against it. Delivered as an injectable collagen scaffold via ultrasound guidance, it polymerises directly on the worn joint surface without requiring surgical access or a large defect cavity. Once in place, the scaffold provides a structural framework that the body's own repair cells can migrate into over time — a process known as acellular matrix-induced chondrogenesis. This is mechanistically distinct from hyaluronic acid, which acts as a lubricant and is cleared within weeks without contributing new matrix. The treatment is outpatient, requires no general anaesthetic, and leaves no incision.

What the clinical evidence shows for thumb CMC arthritis

Published in 2023, the Corain cohort study tracked 43 people with trapeziometacarpal osteoarthritis following a single ChondroFiller injection delivered under image guidance — measuring four outcome domains over six months: pain intensity on the Numeric Rating Scale (NRS), daily functional disability on the DASH questionnaire, grip strength, and pincer strength.

Researchers divided participants by disease stage using the Eaton-Littler classification: Group A covered early disease (Stage I–II) and Group B covered advanced disease (Stage III–IV). Both groups achieved statistically significant improvements at the 30-day assessment, and those gains held or extended at six months. In practical terms, the treatment did not confine its benefits to mild cases — patients with more advanced joint changes showed meaningful reductions in pain and functional recovery across all four measures.

Patients with finger-joint involvement — at the metacarpophalangeal or interphalangeal level — may reasonably ask how far this thumb data applies to them. No equivalent prospective cohort currently exists for ChondroFiller injection at MCP or IP joints; the thumb CMC dataset represents the closest available evidence base for small hand joints as a group. In practice, clinicians use it as a reference point while accumulating case experience across the hand, and candidacy at those sites is assessed individually rather than read directly from published benchmarks.

One further limitation merits acknowledgement: the Corain study was a single prospective cohort without a randomised control arm. Its findings are encouraging and span the full staging range, but the evidence base for ChondroFiller injection in hand joints is still developing.

What the clinic assessment actually involves

The pathway to treatment starts before any appointment is booked. A short online pre-screening tool — eight questions, around two minutes — returns an initial pathway indication based on the joint affected, symptoms, and prior treatments. This gives patients a working sense of whether ChondroFiller injection is likely to be relevant before committing to a clinic visit.

The formal assessment takes place at London Cartilage Clinic, 66 Harley Street — the first UK centre to offer ChondroFiller as an injection pathway. The consultation runs approximately one hour and centres on imaging: any existing MRI scans, X-rays, or reports should be shared ahead of or brought to the appointment. Professor Paul Lee uses this material to map the cartilage defect in detail, assess joint geometry, and identify any factors that might affect suitability.

By the end of the consultation, patients leave with a written treatment plan. How many boxes of ChondroFiller product are required — one, two, or three — is determined at this point once the defect area has been reviewed; it cannot be confirmed beforehand. There is no upper age limit and no defect-size threshold that automatically rules a patient out; the imaging review is the operative step, not a checklist of demographic criteria.

The injection appointment itself

On the day of the injection, the appointment typically runs 30 to 45 minutes from start to finish. Given that ultrasound guidance and the outpatient setting were covered earlier, what matters most here is understanding the sequence and timeline.

Intravenous antibiotic cover is administered as standard at the time of injection — a precautionary measure included in the appointment, not an add-on. The clinician then introduces ChondroFiller Liquid into the joint under live imaging, where it polymerises in situ, coating the worn cartilage surface as a biological collagen scaffold.

Patients sometimes expect to feel an immediate change. The scaffold is in place from the moment the injection is complete, but the repair process it initiates is gradual. Over the following 6 to 12 months, the body's own progenitor cells migrate into the matrix and begin depositing new tissue. Functional improvement tends to develop progressively across that period rather than arriving as a single event.

ChondroFiller Liquid is a CE-marked Class III medical device, manufactured by meidrix biomedicals GmbH and CE-marked in 2013. That regulatory classification reflects the level of clinical scrutiny applied to the product before its use in patient care.

When advanced arthritis changes the treatment plan

Severe changes on X-ray — Kellgren-Lawrence Grade III or IV — raise a different clinical question, and one that does not automatically end at surgical referral.

For patients in this category, a combined treatment plan may be discussed: ChondroFiller injection targeting the worn cartilage and bone surfaces, and Arthrosamid addressing the synovial lining separately. These are not two doses of the same product. ChondroFiller is the regenerative scaffold component — an acellular collagen matrix that recruits the body's own progenitor cells to build new tissue. Arthrosamid is a polyacrylamide hydrogel: a non-regenerative, mechanical product that integrates into the synovial membrane and acts on the joint environment through an entirely different mechanism. Their anatomical targets are distinct, their clinical purposes are distinct, and they are delivered at separate staged appointments, each requiring its own clinical justification.

MRI findings inform that decision but do not determine it. The same Kellgren-Lawrence grade on imaging can correspond to very different joint states in individual patients, which is why suitability for each injection is assessed directly rather than read off a scan.

The Corain et al. data point in the same direction: Eaton-Littler Stage III–IV patients responded comparably to those with early-stage disease, suggesting that a structural severity grade is not a reliable substitute for clinical evaluation. The combined plan extends that logic to end-stage disease — addressing both the cartilage surface and the synovial environment where the available evidence supports doing so.

Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street. Patients can begin the process at londoncartilage.com.